A new formulation of MediciNova’s investigational amyotrophic lateral sclerosis treatment ibudilast (MN-166) given via an intravenous (into the vein) infusion was found to be safe and well tolerated in healthy volunteers. That’s according to data from a recently completed Phase 1 clinical trial that tested the safety and…
News
Biological samples from amyotrophic lateral sclerosis (ALS) patients who took part in the Phase 3 clinical trial of NurOwn, a cell-based therapy, are being donated by BrainStorm Cell Therapeutics to a repository for use by the research community. The samples include blood and spinal fluid (cerebrospinal fluid or CSF)…
ANX005, an experimental medication being developed by Annexon Biosciences for neurodegenerative and autoimmune diseases, resulted in a slowing of disease progression in adults with amyotrophic lateral sclerosis (ALS). That’s according to preliminary data from eight patients taking part in a Phase 2a clinical study (NCT04569435), whose main…
The bacterial strain Lacticaseibacillus rhamnosus HA-114 prevents neurodegeneration and preserves motor function in worm models of amyotrophic lateral sclerosis (ALS), a new study reports. This protective effect was linked to the fat molecules, called fatty acids, found in this strain, which helped restore fat metabolism in the mitochondria —…
A Phase 1 clinical trial has begun dosing adult healthy volunteers to investigate QurAlis Corporation‘s QRL-101, an oral treatment candidate for amyotrophic lateral sclerosis (ALS), the company announced. The first-in-human Phase 1 trial (NCT05667779) aims to assess the safety, tolerability, and pharmacokinetics — the movement of a…
Use of ATH-1105, a small molecule being developed by Athira Pharma to treat amyotrophic lateral sclerosis (ALS), protected against nerve damage and improved motor function in a mouse model of the disease, according to data shared in a recent company presentation. Athira is planning to file an…
Adding a skin patch containing a Chinese herb mixture called Ji Wu Li (JWL) to standard medications significantly slowed disease progression in people with amyotrophic lateral sclerosis (ALS), according to data from a randomized clinical trial. In the trial, called ALS-CHEPLA (ChiCTR200037353), the benefits of the herbal treatment emerged…
Masitinib, an oral medicine developed by AB Science, has won orphan drug status for treating amyotrophic lateral sclerosis (ALS) in Switzerland. The status is granted by the Swiss Agency for Therapeutic Products (Swissmedic) to therapies that seek to treat life-threatening or chronic diseases affecting no more than…
The U.S. Food and Drug Administration (FDA) has granted a Type A meeting to BrainStorm Cell Therapeutics to discuss the agency’s refusal to review NurOwn as a treatment for amyotrophic lateral sclerosis (ALS). According to the FDA, type A meetings are used for “an otherwise stalled product development…
MitoSense and the Centre for Transplantation Technology at Uppsala University are collaborating to harness the power of mitochondria — the energy source for cells — in treating diseases that include amyotrophic lateral sclerosis (ALS), the company announced. MitoSense has developed a patented, first-in-kind mitochondria transplantation technology — coined…
Recent Posts
- ALS Network, ALS United calling for ‘bold’ research proposals for funding
- Study finds common medications that could be repurposed to treat ALS
- New eye imaging approach may help distinguish ALS from Alzheimer’s
- After 15 years as an ALS caregiver, I’m still learning from others
- Early PrimeC use slows ALS progression, reduces complication risk